Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Trusted professionals delivering their expertise over popular topics from emerging data to pragmatic viewpoints.

Explore Leading Voices

Loading polls...

Clinical Updates Calendar

Anticipated Decisions

Approvals

Conferences

Designations

Events This Month

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Home

Clinical Updates Calendar

View All Resources

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Intercalated Gefitinib Plus Chemotherapy Improves DFS in Resected EGFR-Mutant NSCLC Infographic

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-Year Overall Survival Landmark Update

Firmonertinib 160 mg Demonstrates Efficacy in EGFR-Mutated NSCLC With Leptomeningeal Mets

DISCOVER TRENDING TAGS

Home

Clinical Updates Calendar

Get Updates

View All Resources